Frailty in Heart Failure According to the Presence or Absence of Wild-Type Transthyretin Cardiac Amyloidosis
ESC Heart Failure · 01.02.2025 · 12 (1) · 281-289
DOI: 10.1002/ehf2.15026 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 16.09.2024. Verfasst von Amaury Broussier und 12 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, IMRB, Univ Paris Est Creteil, Creteil, France. Hauptthemen laut MEDLINE: Heart Failure, Frailty, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz, Gerontologische Pflege
Abstract (Originalsprache)
Aims
Wild-type transthyretin cardiac amyloidosis (ATTRwt CA) is a common, underdiagnosed cause of heart failure (HF) in the elderly. Concurrent extracardiac amyloid infiltration might be responsible for a specific frailty phenotype. This study aims to compare the prevalence and characteristics of frailty parameters in HF patients, with or without ATTRwt CA.
Methods
In a comparative cross-sectional study, we prospectively included consecutive HF patients with or without ATTRwt CA (the HF + ATTRwt+ and HF + ATTRwt− groups, respectively) between April 2018 and April 2021. Logistic regression models were used to compare the groups with regard to frailty as assessed using multidimensional geriatric tools.
Results
We included 123 patients (68 HF + ATTRwt+ and 55 HF + ATTRwt−). The mean age was 80.9 (standard deviation 6.3) years, 87% were male, 34% had left ventricular systolic dysfunction and 34% were New York Heart Association (NYHA) III. Relative to the HF + ATTRwt− group, patients in the HF + ATTRwt+ group were more likely to have shrinking [odds ratios = 2.9 (95% confidence interval, 1.1 to 1.7), P = 0.03], balance disorders [1.8 (1.1 to 2.8), P = 0.02], memory complaints [2.5, (1.0 to 5.9), P = 0.05] and overactive bladder [1.5 (1.1 to 2.2), P = 0.03], independently of age, sex, NYHA class and diabetes status. The proportion of very frail patients was higher (albeit not significantly) in the HF + ATTRwt+ group than in the HF + ATTRwt− group [2.4 (0.9 to 6.9), P = 0.10].
Conclusions
ATTRwt CA is associated with a specific frailty phenotype. Patients with ATTRwt CA should be screened for frailty and managed collaboratively by cardiologists and geriatricians, with a view to improving quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
- Department of Geriatrics, AP-HP, Hopitaux Universitaires Henri-Mondor, Limeil-Brevannes, France.
- Department of Internal Medicine and Geriatrics, AP-HP, Hopitaux Universitaires Henri-Mondor, Creteil, France.
- Department of Cardiology, Heart Failure and Amyloidosis Unit, AP-HP, Hopitaux Universitaires Henri-Mondor, Creteil, France.
- Department of Public Health, AP-HP, Hopitaux Universitaires Henri-Mondor, Creteil, France.
ORCID-Profile: Amaury Broussier
Zitieren
APA
Broussier, A., Paugam, M., Liu, N., Oghina, S., Kharoubi, M., Lafont, C., Zaroui, A., Galat, A., Hittinger, L., Teiger, E., David, J. P., Bastuji-Garin, S., & Damy, T. (2025). Frailty in Heart Failure According to the Presence or Absence of Wild-Type Transthyretin Cardiac Amyloidosis. ESC Heart Failure, 12(1), 281-289. https://doi.org/10.1002/ehf2.15026
Vancouver
Broussier A, Paugam M, Liu N, Oghina S, Kharoubi M, Lafont C, et al. Frailty in Heart Failure According to the Presence or Absence of Wild-Type Transthyretin Cardiac Amyloidosis. ESC Heart Failure. 2025;12(1):281-289. doi:10.1002/ehf2.15026
BibTeX
@article{Broussier2025,
author = {Broussier, Amaury and Paugam, Marie and Liu, Nina and Oghina, Silvia and Kharoubi, Mounira and Lafont, Charlotte and Zaroui, Amira and Galat, Arnault and Hittinger, Luc and Teiger, Emmanuel and David, Jean Philippe and Bastuji-Garin, Sylvie and Damy, Thibaud},
title = {Frailty in Heart Failure According to the Presence or Absence of Wild-Type Transthyretin Cardiac Amyloidosis},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {1},
pages = {281--289},
doi = {10.1002/ehf2.15026}
}
EUVIMED